Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Steven M. Greenberg, MD, PhD, FAHA, Chair; Wendy C. Ziai, MD, MPH, FAHA, Vice Chair;
Charlotte Cordonnier, MD, PhD; Dar Dowlatshahi, MD, PhD, FAHA; Brandon Francis, MD …

Background Perioperative bleeding is common in patients undergoing noncardiac surgery.
Tranexamic acid is an antifibrinolytic drug that may safely decrease such bleeding. Methods …

METHODS The recommendations were developed as a synthesis and update of evidence
from the literature. They are based on the FIGO Safe Motherhood and Newborn Health …

Importance Tranexamic acid (TXA) is an efficient antifibrinolytic agent; however, concerns
remain about the potential adverse effects, particularly vascular occlusive events, that may …

Background Post-partum haemorrhage is the leading cause of maternal death worldwide.
Early administration of tranexamic acid reduces deaths due to bleeding in trauma patients …

Background Prophylactic administration of tranexamic acid has been associated with
reduced postpartum blood loss after cesarean delivery in several small trials, but evidence …

Background Tranexamic acid (TXA) reduces surgical bleeding and reduces death from
bleeding after trauma and childbirth. However, its effects on thrombotic events and seizures …

Background Tranexamic acid reduces the risk of bleeding among patients undergoing
cardiac surgery, but it is unclear whether this leads to improved outcomes. Furthermore …

Document Reviewers: Moritz WV Wyler von Ballmoos (USA), Mate Petricevic (Croatia), Arie
Pieter Kappetein (Netherlands), Miguel Sousa-Uva (Portugal), Georg Trummer (Germany) …